Idea principal
Across 16 studies, wearable-measured HRV was higher early in the menstrual cycle and lower toward the end, with time-domain differences of 3 to 9%, and was lower in hormonal contraceptive users. Studies defined cycle phases and menopause differently, so the results could not be pooled statistically.
Study design
Revisión de evidencia
Reading basis
Published abstract
Reading focus
Design & applicability
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Wearables now track heart rate variability (HRV, a marker linked to autonomic nervous system function) around the clock, but ovarian hormones may change it in ways that confuse interpretation. The authors reviewed what wearable HRV studies show across the menstrual cycle, hormonal contraceptive use, pregnancy and menopause.
Población y método
Living systematic review. PubMed, Web of Science, IEEE Xplore, SPORTDiscus and Embase were searched from inception to December 2025 using a Participant-Exposure-Outcome framework. Studies were double screened and had to examine wearable-measured HRV across the menstrual cycle in naturally menstruating females, in response to exogenous ovarian hormones, or across another hormonal state such as menopause or pregnancy. Cohort study quality was assessed with the Newcastle-Ottawa Scale. From 299 records, 16 studies were included. Registered on OSF.
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1In naturally menstruating females, HRV was higher at the beginning of the cycle and lower toward the end, with differences in time-domain HRV ranging from 3 to 9%.
- 2Hormonal contraceptive users showed lower HRV, particularly in the late cycle.
- 3HRV tended to decline after menopause with increasing age.
- 4Evidence quality was moderate (7/9 on the Newcastle-Ottawa Scale). Inconsistent classification of cycle phases and menopausal status limited comparability and prevented a quantitative synthesis.
Límites e incertidumbre
- 1Only 16 studies were included, and differing definitions of cycle phase and menopausal status mean the findings are a qualitative summary without pooled estimates.
- 2The 3 to 9% range is small relative to day-to-day HRV variation, and the abstract does not say how many participants were involved or which devices were used.
- 3Age and menopause are entangled, since HRV declines with age anyway, so the menopause finding is hard to separate from ageing.
- 4This reading is based on the abstract only.
Relevancia práctica
If you track HRV and menstruate, expect a gentle drift across your cycle rather than reading every dip as stress or overtraining. Hormonal contraception may sit at a lower baseline. Questions about symptoms or hormones belong with your clinician.
Tus datos
Compare your HRV with your own baseline from the same cycle phase, on the same device and at the same time of night, and use multi-week trends rather than single readings. Logging cycle day alongside HRV, sleep and training load can make the pattern easier to see.
Cómo interpretar la evidencia
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Background
Heart rate variability (HRV) reflects autonomic nervous system function and can now be continuously monitored in real-world settings using wearable technology. However, the influence of ovarian hormones on HRV remains unclear, underscoring the need to synthesize evidence across the female lifespan.
Objective
To examine the association between ovarian hormone profiles and HRV measured by wearable/mobile devices.
Design
Living systematic review.
Data sources
A comprehensive search was conducted in PubMed, Web of Science, IEEE Xplore, SPORTDiscus, and Embase from inception to December 2025. The search followed the Participant (females of any age), Exposure (ovarian hormone profiles), and Outcomes (HRV measured by wearable devices) framework, using a combination of MeSH terms and keyword adaptations. Quality was assessed for cohort studies using the Newcastle-Ottawa Scale.
Eligibility criteria
All studies were independently double screened by title, abstract, and full text. Studies were eligible if they examined differences in HRV measured by a wearable device, across the menstrual cycle in naturally menstruating females, in response to exogenous ovarian hormones, or across another ovarian hormone state such as menopause or pregnancy.
Results
From 299 identified records, 16 studies were included. In naturally menstruating females, HRV was higher at the beginning of the cycle and lower toward the end, with differences in time-domain HRV ranging from 3 to 9%. Hormonal contraceptive users exhibited lower HRV, particularly in the late cycle. Additionally, HRV tended to decline after menopause with increasing age. The quality of evidence in this review was moderate (7/9). Variability in how menstrual cycle phases and menopausal status were classified across studies limited comparability and the ability to synthesize findings quantitatively.
Conclusions
Wearable-derived HRV is associated with differences across the menstrual cycle, oral contraceptive use, and reproductive life stages. This should be considered when presenting HRV metrics to female users. This may improve the interpretation of data for female athletes, patients, or women who track their HRV.
Osf registration
DOI https://doi.org/10.17605/OSF.IO/S4RYW .
Fuentes y atribución
Wearable-Derived Heart Rate Variability Across the Menstrual Cycle, Hormonal Contraceptive Use, and Reproductive Life Stages in Females: A Living Systematic Review.
de Jager E, Caulfield B, Angelidi E, MacNamee B, Holden S.
Sports medicine (Auckland, N.Z.) · 2026-01-17
DOI: 10.1007/s40279-025-02388-y ↗PubMed · 41545627 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
Short-term HRV was higher during slow breathing in 962 military men, injured or not
In 962 military men (median age 37.6 years), every short-term heart rate variability (HRV) measure was higher during slow breathing at six breaths a minute than during spontaneous breathing, injured or not; in fast resting breathers RMSSD rose from 15.57 to 21.89 ms. It was one session in a fixed order, so it shows an immediate effect, not lasting benefit.
European Journal of Applied Physiology
Cold-water immersion: no strength gain, briefly weaker jumps, soreness relief uncertain
Across 22 randomised trials (375 participants, mostly men), one cold-water immersion after exercise did not change maximal isometric strength (g 0.08, 95% CI −0.11 to 0.26) and was followed by weaker jumping straight afterwards (g −0.68), gone by 24–48 hours. Lower soreness and creatine kinase looked favourable but weakened in sensitivity checks, and certainty was low to very low.
PeerJ
Cold-water immersion after hard exercise: less soreness, better power, no strength gain
In a meta-analysis of 52 randomised trials, cold-water immersion after high-intensity exercise was followed 24 hours later by lower soreness (SMD −0.89), higher perceived recovery (0.66) and better muscular power (0.22), with no effect on strength. Participants could not be blinded, most were men, and many pooled results rest on few studies with high heterogeneity.
Sports Medicine
Acute:chronic workload ratio: no evidence it can reduce injury risk, authors argue
The authors argue there is no evidence for using the acute:chronic workload ratio (ACWR) in training-load management or to reduce injury risk: no study has properly estimated a causal effect, and the ratio is statistically inaccurate and ambiguous. This is a methodological critique, not a new data analysis, so it does not show that training load is unrelated to injury.
International Journal of Sports Physiology and Performance

